Roche Holding AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public

Established: 1896-01-15

Employees: 103.6K

Market Cap: $270.5B

Website: http://www.roche.com

Clinical Trials

A Proof-of-Concept Study of Faricimab (RO6867461) in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)

Phase 2

Completed

Conditions: Choroidal Neovascularization

Interventions: Drug: Ranibizumab
Drug: Faricimab
Drug: Sham Procedure

First Posted Date: 2015-06-30

Last Posted Date: 2020-11-12

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 273

Registration Number: NCT02484690

Locations: 🇺🇸
Retina Consultants, San Diego, Poway, California, United States
🇺🇸
New England Retina Associates, Hamden, Connecticut, United States
🇺🇸
Austin Retina Associates, Austin, Texas, United States

and more 49 locations

A Study of RO5186582 in Down Syndrome Among Children 6 to 11 Years of Age

Phase 2

Terminated

Conditions: Down Syndrome

Interventions: Drug: Placebo
Drug: RO5186582

First Posted Date: 2015-06-30

Last Posted Date: 2017-07-06

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 45

Registration Number: NCT02484703

Locations: 🇺🇸
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
🇺🇸
Emory University School of Medicine; Department of Human Genetics & Pediatrics, Decatur, Georgia, United States
🇺🇸
Duke Clin Rsch Institute, Durham, North Carolina, United States

and more 6 locations

Safety of Xeloda in Solid Tumours

Completed

Conditions: Metastatic Breast Cancer, Colon Cancer

Interventions: Drug: Xeloda
Drug: Docetaxel

First Posted Date: 2015-06-24

Last Posted Date: 2017-02-17

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 1268

Registration Number: NCT02479217

A Study of Pertuzumab in Participants With Prostate Cancer

Phase 2

Terminated

Conditions: Prostate Cancer

Interventions: Drug: Pertuzumab

First Posted Date: 2015-06-24

Last Posted Date: 2015-09-18

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 68

Registration Number: NCT02480010

A Study of Disease Progression in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Terminated

Conditions: Geographic Atrophy

Interventions: Other: No intervention

First Posted Date: 2015-06-24

Last Posted Date: 2019-08-20

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 296

Registration Number: NCT02479386

Locations: 🇵🇱
Klinika Okulistyki Ogolnej w Lublinie, Lublin, Poland
🇵🇱
SPEKTRUM Osrodek Okulistyki Klinicznej, Wroclaw, Poland
🇺🇸
Northwest Arkansas Retina Associates, Springdale, Arkansas, United States

and more 88 locations

A Prospective Study to Collect High-Quality Documentation of Bleeds, Health-Related Quality of Life (HRQoL), and Safety Outcomes in Patients With Hemophilia A Treated With Standard-of-Care Treatment

Completed

Conditions: Hemophilia A

Interventions: Drug: FVIII Replacement
Drug: Bypassing Agents

First Posted Date: 2015-06-22

Last Posted Date: 2017-05-30

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 221

Registration Number: NCT02476942

Locations: 🇺🇸
University of Colorado Denver, Children's Hospital, Aurora, Colorado, United States
🇺🇸
Santa Monica Oncology Center, Santa Monica, California, United States
🇺🇸
Georgetown Uni Medical Center; Lombardi Cancer Center, Washington, D.C., District of Columbia, United States

and more 32 locations

A Study of Rituximab in Combination With Chemotherapy in Relapsed/Refractory Follicular Lymphoma

Completed

Conditions: Lymphoma, Follicular

Interventions: Drug: Chemotherapy
Drug: Rituximab

First Posted Date: 2015-06-16

Last Posted Date: 2017-08-01

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 41

Registration Number: NCT02472756

Locations: 🇷🇸
Institute of Hematology, Belgrade, Serbia
🇷🇸
Clinical Center Kragujevac, Kragujevac, Serbia
🇷🇸
Clinic of Haematology Cc Nis, NIS, Serbia

and more 3 locations

A Study to Investigate the Effect of CYP3A Inhibition on the Pharmacokinetics of RG1662 in Healthy Subjects

Phase 1

Completed

Conditions: Healthy Patient Study

Interventions: Drug: RG1662
Drug: itraconazole

First Posted Date: 2015-06-12

Last Posted Date: 2016-08-26

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 12

Registration Number: NCT02470832

Safety and Efficacy of Bevacizumab in Combination With Carboplatin and Paclitaxel for Metastatic, Recurrent or Persistent Cervical Cancer

Phase 2

Completed

Conditions: Cervical Cancer

Interventions: Drug: Bevacizumab
Drug: Carboplatin
Drug: Paclitaxel

First Posted Date: 2015-06-10

Last Posted Date: 2019-06-03

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 152

Registration Number: NCT02467907

Locations: 🇬🇷
IASO, Athens, Greece
🇨🇴
Oncólogos de Occidente, Pereira, Colombia
🇲🇽
Instituto Nacional de Cancerologia; Oncology, Distrito Federal, Mexico

and more 40 locations

A Study to Evaluate the Safety of Lebrikizumab Compared to Topical Corticosteroids in Adult Patients With Atopic Dermatitis

Phase 2

Completed

Conditions: Atopic Dermatitis

Interventions: Drug: Lebrikizumab
Drug: Topical Corticosteroid Creams (Triamcinolone acetonide 0.1% and Hydrocortisone 2.5%)

First Posted Date: 2015-06-08

Last Posted Date: 2020-01-27

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 55

Registration Number: NCT02465606

Locations: 🇺🇸
Allergy and Asthma Relief Experts, Granada Hills, California, United States
🇺🇸
T. Joseph Raoof Md, Inc., Encino, California, United States
🇺🇸
Allergy and Asthma Associates of Southern California - CRN, Mission Viejo, California, United States

and more 16 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy